crenolanib
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01243346)
Timeline
Indications
Mechanism of action
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
FLT3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1.O=S(=O)(O)c1ccccc1- Mol. weight
- 601.73 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2146086 ↗
Also known as
- 596-26
- aro-002-26
- aro-002-26
- cp-868
- crenolanib besylate
- crenolanib besylate
- crenolanib besylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02400255 | Phase 2 | Sep 1, 2015 | Arog Pharmaceuticals, Inc. |
| NCT02400281 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Arog Pharmaceuticals, Inc. |
| NCT01657682 | Phase 2 | Oct 1, 2012 | Arog Pharmaceuticals, Inc. |
| NCT01522469 | Phase 2 | Jul 1, 2012 | Arog Pharmaceuticals, Inc. |
| NCT01243346 | Phase 2 | Apr 1, 2011 | Arog Pharmaceuticals, Inc., Oregon Health and Science University, Temple University |
| NCT03620318 | N/A | — | Arog Pharmaceuticals, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arog Pharmaceuticals, Inc. | For profit | 6 | 6 | 2 | 2011 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1